With drug target screening in DrugBank,27 17 available phospho-targets with FDA-approved drugs were identified, of which p-EGFR and p-SYK inhibitors have been previously applied in pulmonary fibrosis treatment.20–22 These results indicated that p-EGFR and p-SYK might be potential targets for silicosis treatment (Fig. 4d). The gene discussed is SYK; the disease is silicosis.